Frazier Healthcare Secures Minority Investment from Goldman Sachs' Petershill

Frazier Healthcare Secures Minority Investment from Goldman Sachs’ Petershill

Frazier Healthcare Secures Minority Investment from Goldman Sachs’ Petershill Frazier Healthcare Partners, a prominent healthcare-focused private capital firm based in Seattle, has announced a strategic minority investment from Petershill at Goldman Sachs Alternatives (“Petershill”). While the specific terms of the…

Read MoreFrazier Healthcare Secures Minority Investment from Goldman Sachs’ Petershill
RADIANT Trial Shows Significant Glycemic Gains with Omnipod® 5 After MDI Transition

RADIANT Trial Shows Significant Glycemic Gains with Omnipod® 5 After MDI Transition

RADIANT Trial Shows Significant Glycemic Gains with Omnipod® 5 After MDI Transition Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology through its Omnipod® brand, has released new clinical data from its RADIANT study, demonstrating significant glycemic…

Read MoreRADIANT Trial Shows Significant Glycemic Gains with Omnipod® 5 After MDI Transition
Forth Tx Debuts with Sofinnova’s Support to Transform Fibrosis Treatment

Forth Tx Debuts with Sofinnova’s Support to Transform Fibrosis Treatment

Forth Tx Debuts with Sofinnova’s Support to Transform Fibrosis Treatment Forth Therapeutics (Forth Tx), a biotechnology company pioneering next-generation precision therapeutics for fibrosis, officially launches today with significant backing from Sofinnova Partners, a leading European life sciences venture capital firm,…

Read MoreForth Tx Debuts with Sofinnova’s Support to Transform Fibrosis Treatment
BioClec Launches to Transform Alzheimer’s Treatment with Sofinnova’s Backing

BioClec Launches to Transform Alzheimer’s Treatment with Sofinnova’s Backing

BioClec Launches to Transform Alzheimer’s Treatment with Sofinnova’s Backing BioClec, a pioneering biotechnology company dedicated to revolutionizing treatments for Alzheimer’s disease, has officially launched. The company emerges from Biovelocita II, Sofinnova Partners’ €165 million biotech acceleration program, and is focused…

Read MoreBioClec Launches to Transform Alzheimer’s Treatment with Sofinnova’s Backing